Subscribe To
SGTX / Why Is Sigilon Therapeutics (SGTX) Stock Up 691% Today?
SGTX News
By Zacks Investment Research
June 30, 2023
Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly
Eli Lilly (LLY) is set to acquire Sigilon (SGTX) for $14.92 per share, in cash, along with a contingent value right of $111.64 per share. more_horizontal
By InvestorPlace
June 29, 2023
Why Is Sigilon Therapeutics (SGTX) Stock Up 691% Today?
Sigilon Therapeutics (NASDAQ: SGTX ) stock is rocketing on Thursday morning after Eli Lilly (NYSE: LLY ) agrees to acquire the company. The acquisiti more_horizontal
By GlobeNewsWire
March 8, 2022
Sigilon Therapeutics to Present at the Barclays Global Healthcare Conference
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop function more_horizontal
By Zacks Investment Research
March 2, 2022
4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry
Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additi more_horizontal
By Zacks Investment Research
March 2, 2022
4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry
Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additi more_horizontal
By Zacks Investment Research
March 2, 2022
4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry
Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additi more_horizontal
By Zacks Investment Research
February 7, 2022
Bears are Losing Control Over Sigilon Therapeutics, Inc. (SGTX), Here's Why It's a 'Buy' Now
Sigilon Therapeutics, Inc. (SGTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled more_horizontal
By Zacks Investment Research
February 7, 2022
Bears are Losing Control Over Sigilon Therapeutics, Inc. (SGTX), Here's Why It's a 'Buy' Now
Sigilon Therapeutics, Inc. (SGTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled more_horizontal